Posoleucel治疗肾移植受者BK病毒血症:多中心随机双盲安慰剂对照2期试验
Posoleucel总体安全耐受,与安慰剂相比BK病毒血症下降幅度更大,且病毒血症下降伴随BK病毒特异性T细胞循环频率增加。
要点
- Posoleucel在肾移植受者中总体安全、耐受良好,未发生移植物抗宿主病或细胞因子释放综合征。
- Posoleucel组BK病毒血症下降幅度大于安慰剂组,且与BK病毒特异性T细胞频率增加同步。
- T细胞受体可变β链测序证实了posoleucel的存在与持续。
核心结论
- Posoleucel总体安全、耐受良好,与安慰剂相比与更大程度的BK病毒血症下降相关。
研究设计与样本
- 2期双盲研究,肾移植受者伴BK病毒血症按1:1:1随机接受posoleucel每周一次共3周后每14天一次或每28天一次、或安慰剂治疗12周,治疗后随访12周。
主要发现
- 研究者判定为治疗相关的不良事件比例在posoleucel每14天组为20%(4/20)、每28天组为18%(4/22)、安慰剂组为26%(5/19)。
- 任何组中3–4级不良事件或严重不良事件均未被判定为治疗相关。
- 未发生死亡、移植物抗宿主病或细胞因子释放综合征;3例发生同种异体移植物排斥,但均未被研究者判定为治疗相关。
- 在posoleucel受者中,BK病毒血症下降与BK病毒特异性T细胞循环频率增加相关,T细胞受体测序证实了posoleucel的存在与持续。
临床怎么用
- Posoleucel作为现货型同种异体多病毒特异性T细胞研究性疗法,靶向BK病毒及腺病毒、巨细胞病毒、EB病毒、人疱疹病毒6型和JC病毒。
- 肾移植受者BK病毒感染目前无获批治疗,该研究为BK病毒血症的免疫治疗提供了2期安全性及病毒学下降证据。
局限性
- 随访时间相对较短。
- 研究缺乏检测临床结局显著差异的把握度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Posoleucel was generally safe, well tolerated, and associated with a greater reduction of BK viremia compared with placebo. BK viremia reduction occurred coincident with an increase in the circulating frequency of BK virus–specific T cells in posoleucel recipients. The presence and persistence of posoleucel was confirmed by T-cell receptor variable β sequencing. BACKGROUND: Kidney transplant recipients with BK virus infection are at risk of developing BK virus–associated nephropathy, allograft rejection, and subsequent graft loss. There are no approved treatments for BK virus infection. Posoleucel is an off-the-shelf, allogeneic, multivirus-specific T-cell investigational therapy targeting BK virus, as well as five other opportunistic viruses: adenovirus, cytomegalovirus, Epstein–Barr virus, human herpesvirus 6, and John Cunningham virus. METHODS: In this phase 2, double-blind study, kidney transplant recipients with BK viremia were randomized 1:1:1 to receive posoleucel weekly for 3 weeks and then every 14 days (bi-weekly dosing) or every 28 days (monthly dosing) or placebo for 12 weeks. Participants were followed for 12 weeks after completing treatment. The primary objective was safety; the secondary objective was plasma BK viral load reduction. RESULTS: Sixty-one participants were randomized and dosed. Baseline characteristics were similar across groups. No deaths, graft-versus-host disease, or cytokine release syndrome occurred. The proportion of patients who had adverse events (AEs) judged by the investigators to be treatment-related was slightly lower in recipients of posoleucel: 20% (4 of 20 patients) and 18% (4 of 22) in those infused on a bi-weekly and monthly schedule, respectively, and 26% (5 of 19) in placebo recipients. None of the grade 3–4 AEs or serious AEs in any group were deemed treatment-related. No deaths, graft-versus-host disease, or cytokine release syndrome occurred. Three participants had allograft rejection, but none were deemed treatment-related by investigators. In posoleucel recipients, BK viremia reduction was associated with an increase in the circulating frequency of BK virus–specific T cells, and the presence and persistence of posoleucel was confirmed by T-cell receptor sequencing. CONCLUSIONS: Posoleucel was generally safe, well tolerated, and associated with a larger reduction of BK viremia compared with placebo. Limitations of this study include the relatively short duration of follow-up and lack of power to detect significant differences in clinical outcomes. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER:: Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia, NCT04605484.
引用
- Chandraker A, Regmi A, Gohh R, et al. Posoleucel in Kidney Transplant Recipients with BK Viremia: Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. J Am Soc Nephrol. 2024. PMID: 38470444. doi:10.1681/ASN.0000000000000329
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。